Novo has returned for Milestone's latest round, having led its $55m series C last year, helping the cardiovascular drug developer's total funding to $167m.

Canada-based cardiovascular therapy developer Milestone Pharmaceuticals has closed an $80m financing round that included pharmaceutical firm Novo, increasing its overall funding to more than $167m. The round was led by RTW Investments and included Venrock Healthcare Capital Partners, Boxer Capital, Forbion, Domain Associates, BDC Capital, Pappas Capital, Go Capital, Fonds de solidarit√© FTQ and funds…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.